Anti-NANP antibody and treatment efficacy in patients with acute uncomplicated falciparum malaria attacks

Parasite Immunology

Volumn 22, Issue 11, 2000, Pages 589-593

  Robert, V ^a,b,c,d,e,f   Roeffen, W ^a,b,c,d,e   Brasseur, P ^a,b,c,d,e   Aribot, G ^a,b,c,d,e   Verhave, J P ^a,b,c,d,e   Roussilhon, C ^a,b,c,d,e  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HÔPITAL CHARLES NICOLLE   (France)

^d INSTITUT PASTEUR DE DAKAR   (Senegal)

^e INSTITUT PASTEUR   (France)

^f INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

Author keywords

Acute uncomplicated malaria; Antigametocyte antibodies; Antimerozoite antibodies; Antisporozoite antibodies; Chloroquine; In vivo sensitivity assay; Plasmodium falciparum; Senegal

Indexed keywords

CHLOROQUINE; PROTOZOON ANTIBODY; SPOROZOITE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AFRICA; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE TRANSMISSION; GAMETOCYTE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE STATUS; LIFE CYCLE; MALARIA FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; HUMANS; MALARIA, FALCIPARUM; MEMBRANE GLYCOPROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TREATMENT OUTCOME;

EID: 0033763901     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.2000.00340.x     Document Type: Article

References (20)

1. Impairment of Plasmodium falciparum-specific antibody response in severe malaria
2. Detection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides
3. Levels of antibodies to Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are persistent in the absence of reinfection
4. Sensitive radioimmunoassay and enzyme-linked immunosorbent assay for the simultaneous determination of chloroquine and its metabolites in biological fluids
5. Epidemiology of malaria
6. Epidemiological evidence for an association between chloroquine resistance of Plasmodium falciparum and its immunological properties
7. Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population
8. Malaria pathogenesis
9. A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulfadoxine in Gambian children with uncomplicated malaria
10. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes
11. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon
12. Gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparam malaria in West Africa
13. Dynamiques de la gametocytemie a Plasmodium falciparum en fonction de la reponse therapeutique a la chloroquine en zone de mesoendemie palustre
14. A comparison of transmission-blocking activity with reactivity in a Plasmodium falciparum 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay
15. Association between anti Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon
16. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria
17. Tests in vivo de chimiosensibilite de Plasmodium falciparum a la chloroquine au Senegal: Evolution de la resistance et estimation de l'efficacite therapeutique
18. Malaria morbidity among children exposed to low seasonal transmission in Dakar, Senegal and its implications for malaria control in tropical Africa
19. Impact of chloroquine resistance on malaria mortality
20. Polymorphism of the Pfmdr1 gene and chloroquine resistance in Plasmodium falciparum in The Gambia